When challenged with gradient concentration of clinical CRC drugs, including chemotherapeutics, oxaliplatin and irinotecan and targeted agent, regorafenib, CRC cells with TOX3 knockdown exhibited enhanced drug sensitivity, whereas TOX3 overexpression suppressed the sensitivity to these clinical drugs (Figs 3A and S4A). This evidence concerns the gene TOX3 and colorectal carcinoma.